REGENXBIO Inc. and Nippon Shinyaku Co., Ltd. announced an exclusive strategic partnership on January 14, 2025, for the development and commercialization of RGX-121 for Mucopolysaccharidosis II (MPS II) and RGX-111 for Mucopolysaccharidosis I (MPS I).
Under the agreement, REGENXBIO will receive $110 million at closing and up to an additional $700 million in potential development, regulatory, and sales milestones. REGENXBIO will also receive double-digit royalties on net sales in the U.S. and Asia.
REGENXBIO retains all rights to the potential Priority Review Voucher for RGX-121. The transaction is expected to close by the end of the first quarter of 2025, subject to customary conditions, and REGENXBIO will lead manufacturing for both products.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.